Minireviews
Copyright ©The Author(s) 2015.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 219-227
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.219
Table 2 Clinical trials evaluating the efficacy of Janus kinase inhibitor and integrin antagonists in ulcerative colitis patients
DrugTrialStudy populationProtocolFollow-up (wk)Outcome
TofacitinibSandborn et al[21]310.5 mg po twice daily832% (P = 0.39) clinical response at week 8
13% (P = 0.76) clinical remission at week 8
333 mg po twice daily848% (P = 0.55) clinical response at week 8
33% (P = 0.01) clinical remission at week 8
3310 mg po twice daily861% (P = 0.10) clinical response at week 8
48% (P < 0.001) clinical remission at week 8
4915 mg po twice daily878% (P < 0.001) clinical response at week 8
41% (P < 0.001) clinical remission at week 8
VedolizumabGEMINI 1[32]225300 mg iv at weeks 0, 2 and 6647.1% (P < 0.001) clinical response at week 6
16.9% (P = 0.00) clinical remission at week 6
122300 mg iv at week 0, 2, 6 and every 4 wk5244.8% (P < 0.001) clinical remission at week 52
125300 mg iv at week 0, 2, 6 and every 8 wk5241.8% (P < 0.001) clinical remission at week 52
EtrolizumabVermeire et al[35]39100 mg sc at week 0, 4 and 81021% (P = 0.0040) clinical remission at week 10
39420 mg sc loading dose then 300 mg at week 2, 4, and 81010% (P = 0.048) clinical remission at week 10